Skip to main content
. 2017 Aug 4;8(57):96482–96495. doi: 10.18632/oncotarget.19946

Figure 5. ATM suppression on oncogenic function of PRKCI in vivo.

Figure 5

A. PRKCI-knockdown KOC-7c cells, B. PRKCI-overexpressing ES2 cells and C. PRKCI-overexpressing TOV21G cells were intraperitoneally injected into athymic nude mice (10 mice per group). The mice were allowed to grow for 1-3 week for tumor formation. After that, each group of mice were randomly divided into two (5 mice per group) for ATM treatment. Mice in the ATM treatment groups were intramuscularly injected with 20mg/kg/day of ATM for 14 consecutive days. Mice in the control groups were intramuscularly injected with equal volume of 1X PBS solution. After ATM treatment, mice were sacrificed and xenograft tumor samples were collected. Representative photos of xenograft tumor samples were shown. Average tumor weight of each group was shown in the bar chart at the right panel. *p < 0.05.